

Nicholas J Shaheen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/766889/publications.pdf>

Version: 2024-02-01

128
papers

14,094
citations

41258

49
h-index

20307

116
g-index

131
all docs

131
docs citations

131
times ranked

10828
citing authors

#	ARTICLE	IF	CITATIONS
1	Eosinophilic esophagitis: Updated consensus recommendations for children and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 3-20.e6.	1.5	1,839
2	Burden of Gastrointestinal Disease in the United States: 2012 Update. <i>Gastroenterology</i> , 2012, 143, 1179-1187.e3.	0.6	1,725
3	Radiofrequency Ablation in Barrett's Esophagus with Dysplasia. <i>New England Journal of Medicine</i> , 2009, 360, 2277-2288.	13.9	1,348
4	Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. <i>Gastroenterology</i> , 2019, 156, 254-272.e11.	0.6	1,040
5	Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. <i>Gastroenterology</i> , 2015, 149, 1731-1741.e3.	0.6	793
6	The Burden of Gastrointestinal and Liver Diseases, 2006. <i>American Journal of Gastroenterology</i> , 2006, 101, 2128-2138.	0.2	577
7	A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. <i>Gastrointestinal Endoscopy</i> , 2014, 79, 577-585.e4.	0.5	384
8	Prevalence of Eosinophilic Esophagitis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 589-596.e1.	2.4	359
9	Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission. <i>Science Translational Medicine</i> , 2011, 3, 112re4.	5.8	310
10	Clinical, Endoscopic, and Histologic Findings Distinguish Eosinophilic Esophagitis From Gastroesophageal Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1305-1313.	2.4	305
11	Barrett's oesophagus. <i>Lancet, The</i> , 2009, 373, 850-861.	6.3	293
12	Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 680-685.	0.5	262
13	Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. <i>Gastroenterology</i> , 2022, 162, 621-644.	0.6	254
14	A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. <i>Journal of Infectious Diseases</i> , 2016, 214, 55-64.	1.9	251
15	Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 203-231.	1.0	204
16	Accuracy of the Eosinophilic Esophagitis Endoscopic Reference Score in Diagnosis and Determining Response to Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 31-39.	2.4	182
17	Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: A randomized, controlled trial. <i>Hepatology</i> , 2005, 41, 588-594.	3.6	176
18	Upper Endoscopy for Gastroesophageal Reflux Disease: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. <i>Annals of Internal Medicine</i> , 2012, 157, 808.	2.0	156

#	ARTICLE	IF	CITATIONS
19	Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. <i>Modern Pathology</i> , 2015, 28, 383-390.	2.9	152
20	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1363-1373.	5.1	133
21	Randomised clinical trial: high-dose acid suppression for chronic cough - a double-blind, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 225-234.	1.9	125
22	Dietary Elimination Therapy Is an Effective Option for Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1272-1279.	2.4	117
23	Markers of Eosinophilic Inflammation for Diagnosis of Eosinophilic Esophagitis and Proton Pump Inhibitor-Responsive Esophageal Eosinophilia: A Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 2015-2022.	2.4	113
24	Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 65-73.e5.	0.6	113
25	Utility of a Noninvasive Serum Biomarker Panel for Diagnosis and Monitoring of Eosinophilic Esophagitis: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 821-827.	0.2	102
26	Outcomes of Esophageal Dilation in Eosinophilic Esophagitis: Safety, Efficacy, and Persistence of the Fibrostenotic Phenotype. <i>American Journal of Gastroenterology</i> , 2016, 111, 206-213.	0.2	96
27	Natural history of eosinophilic esophagitis: a systematic review of epidemiology and disease course. <i>Ecological Management and Restoration</i> , 2018, 31, .	0.2	94
28	Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia. <i>Gastroenterology</i> , 2017, 152, 993-1001.e1.	0.6	91
29	Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 495-503.e8.	2.4	90
30	Morbidity and mortality after surgery for nonmalignant colorectal polyps. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 243-250.e2.	0.5	88
31	Optimal Histologic Cutpoints for Treatment Response in Patients With Eosinophilic Esophagitis: Analysis of Data From a Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 226-233.e2.	2.4	88
32	Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 348-355.	0.5	87
33	Esophageal Eosinophilia is Increased in Rural Areas With Low Population Density: Results From a National Pathology Database. <i>American Journal of Gastroenterology</i> , 2014, 109, 668-675.	0.2	82
34	Quality Indicators for the Management of Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium. <i>Gastroenterology</i> , 2015, 149, 1599-1606.	0.6	81
35	Predictors of Response to Steroid Therapy for Eosinophilic Esophagitis and Treatment of Steroid-Refractory Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 452-458.	2.4	80
36	Safety and efficacy of endoscopic spray cryotherapy for Barrett's dysplasia: results of the National Cryospray Registry. <i>Ecological Management and Restoration</i> , 2016, 29, 241-247.	0.2	77

#	ARTICLE	IF	CITATIONS
37	The extremely narrow-caliber esophagus is a treatment-resistant subphenotype of eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 1142-1148.	0.5	72
38	Food elimination diets are effective for long-term treatment of adults with eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 836-844.	1.9	71
39	Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. <i>American Journal of Gastroenterology</i> , 2002, 97, 1319-1327.	0.2	70
40	Diminishing Effectiveness of Long-Term Maintenance Topical Steroid Therapy in PPI Non-Responsive Eosinophilic Esophagitis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e97.	1.3	69
41	Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. <i>Gastroenterology</i> , 2018, 154, 1273-1281.e3.	0.6	67
42	Evaluation of Histologic Cutpoints for Treatment Response in Eosinophilic Esophagitis. <i>Journal of Gastroenterology and Hepatology Research</i> , 2015, 4, 1780-1787.	0.2	61
43	Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus. <i>Gastroenterology</i> , 2018, 155, 316-326.e6.	0.6	60
44	Control of inflammation decreases the need for subsequent esophageal dilation in patients with eosinophilic esophagitis. <i>Ecological Management and Restoration</i> , 2017, 30, 1-7.	0.2	59
45	<i>Helicobacter pylori</i> Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. <i>American Journal of Gastroenterology</i> , 2018, 113, 1148-1155.	0.2	57
46	Alcohol and the Risk of Barrett's Esophagus: A Pooled Analysis from the International BEACON Consortium. <i>American Journal of Gastroenterology</i> , 2014, 109, 1586-1594.	0.2	55
47	Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 647-656.e1.	2.4	54
48	Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial. <i>Gut</i> , 2013, 62, 1248-1255.	6.1	52
49	Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2010, 72, 490-496.e1.	0.5	51
50	Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV-Negative Men After Single and Multiple Dosing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 39-44.	0.9	48
51	A Clinical Prediction Tool Identifies Cases of Eosinophilic Esophagitis Without Endoscopic Biopsy: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 1347-1354.	0.2	40
52	Gastroesophageal Reflux Disease as an Etiology of Sleep Disturbance in Subjects with Insomnia and Minimal Reflux Symptoms: A Pilot Study of Prevalence and Response to Therapy. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1493-1499.	1.1	39
53	Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. <i>Gut</i> , 2017, 66, 1739-1747.	6.1	38
54	Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	38

#	ARTICLE	IF	CITATIONS
55	Effects of the Learning Curve on Efficacy of Radiofrequency Ablation for Barrett's Esophagus. <i>Gastroenterology</i> , 2015, 149, 890-896.e2.	0.6	37
56	Cost Utility of Competing Strategies to Prevent Endoscopic Transmission of Carbapenem-Resistant Enterobacteriaceae. <i>American Journal of Gastroenterology</i> , 2015, 110, 1666-1674.	0.2	37
57	Cost Utility Analysis of Topical Steroids Compared With Dietary Elimination for Treatment of Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 841-849.e1.	2.4	36
58	Clinical and Molecular Factors Associated With Histologic Response to Topical Steroid Treatment in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1081-1088.e2.	2.4	32
59	Prior Fundoplication Does not Improve Safety or Efficacy Outcomes of Radiofrequency Ablation: Results from the U.S. RFA Registry. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 21-29.	0.9	31
60	Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. <i>Carcinogenesis</i> , 2014, 35, 2740-2747.	1.3	31
61	Risk of Esophageal Adenocarcinoma Decreases With Height, Based on Consortium Analysis and Confirmed by Mendelian Randomization. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1667-1676.e1.	2.4	30
62	Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2016, 111, 1528-1535.	0.2	28
63	The esophageal biopsy "cepull" sign: a highly specific and treatment-responsive endoscopic finding in eosinophilic esophagitis (with video). <i>Gastrointestinal Endoscopy</i> , 2016, 83, 92-100.	0.5	28
64	A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma. <i>Ecological Management and Restoration</i> , 2019, 32, .	0.2	26
65	A Newly Identified Susceptibility Locus near <i>FOXP1</i> Modifies the Association of Gastroesophageal Reflux with Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1739-1747.	1.1	24
66	Safety and efficacy of endoscopic spray cryotherapy for esophageal cancer. <i>Ecological Management and Restoration</i> , 2017, 30, 1-7.	0.2	22
67	MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium. <i>PLoS ONE</i> , 2015, 10, e0128617.	1.1	21
68	White Paper AGA: Optimal Strategies to Define and Diagnose Gastroesophageal Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1162-1172.	2.4	21
69	When to consider endoscopic ablation therapy for Barrett's esophagus. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 361-366.	1.0	20
70	Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients. <i>Cancer Prevention Research</i> , 2016, 9, 528-533.	0.7	16
71	Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1598-1606.e4.	2.4	16
72	No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2227-2235.e1.	2.4	16

#	ARTICLE	IF	CITATIONS
73	Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Gastroenterology</i> , 2020, 159, 2065-2076.e1.	0.6	16
74	A prospective multicenter study using a new multiband mucosectomy device for endoscopic resection of early neoplasia in Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 647-654.	0.5	15
75	Distal esophagus is the most commonly involved site for strictures in patients with eosinophilic esophagitis. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.2	15
76	Practice patterns and adherence to clinical guidelines for diagnosis and management of eosinophilic esophagitis among gastroenterologists. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.2	15
77	Randomised clinical trial: the 5-HT ₄ agonist revexepride in patients with gastroesophageal reflux disease who have persistent symptoms despite PPI therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 649-661.	1.9	14
78	Progression of Barrett's esophagus, crypt dysplasia, and low-grade dysplasia diagnosed by wide-area transepithelial sampling with 3-dimensional computer-assisted analysis: a retrospective analysis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 410-418.e1.	0.5	14
79	Editorial: What Is Behind the Remarkable Increase in Esophageal Adenocarcinoma?. <i>American Journal of Gastroenterology</i> , 2014, 109, 345-347.	0.2	13
80	Determination of a treatment response threshold for the Eosinophilic Esophagitis Endoscopic Reference Score. <i>Endoscopy</i> , 2022, 54, 635-643.	1.0	13
81	Inverse Association Between Gluteofemoral Obesity and Risk of Barrett's Esophagus in a Pooled Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1412-1419.e3.	2.4	12
82	Combination Therapy With Elimination Diet and Corticosteroids Is Effective for Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2800-2802.	2.4	12
83	Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2701-2709.e3.	2.4	12
84	Utility of major basic protein, eotaxin-3, and mast cell tryptase staining for prediction of response to topical steroid treatment in eosinophilic esophagitis: analysis of a randomized, double-blind, double dummy clinical trial. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.2	12
85	A Model Using Clinical and Endoscopic Characteristics Identifies Patients at Risk for Eosinophilic Esophagitis According to Updated Diagnostic Guidelines. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1824-1834.e2.	2.4	11
86	Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. <i>Carcinogenesis</i> , 2021, 42, 369-377.	1.3	11
87	Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. <i>International Journal of Cancer</i> , 2016, 138, 1146-1152.	2.3	10
88	Clinical features and time trends associated with an endoscopically normal esophagus in active eosinophilic esophagitis. <i>Endoscopy</i> , 2021, 53, 886-892.	1.0	10
89	Compounded Oral Viscous Budesonide is Effective and Provides a Durable Response in Eosinophilic Esophagitis. <i>HSOA Journal of Gastroenterology & Hepatology Research</i> , 2018, 7, 2509-2515.	0.1	10
90	Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett's Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium. <i>PLoS ONE</i> , 2015, 10, e0138738.	1.1	9

#	ARTICLE	IF	CITATIONS
91	Buried Barrett's Esophagus—a Sheep in Sheep's Clothing. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1281-1283.	0.9	9
92	From Heartburn to Barrett's Esophagus, and Beyond. <i>World Journal of Surgery</i> , 2017, 41, 1698-1704.	0.8	9
93	Esophageal Mucosal Breaks in Gastroesophageal Reflux Disease Partially Responsive to Proton Pump Inhibitor Therapy. <i>American Journal of Gastroenterology</i> , 2013, 108, 529-534.	0.2	8
94	Pleiotropic Analysis of Cancer Risk Loci on Esophageal Adenocarcinoma Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1801-1803.	1.1	7
95	Endoscopic Treatment of High-Grade Dysplasia and Early Esophageal Cancer. <i>World Journal of Surgery</i> , 2017, 41, 1705-1711.	0.8	7
96	Prevalence and Incidence of Intestinal Metaplasia and Dysplasia of Gastric Cardia in Patients With Barrett's Esophagus After Endoscopic Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 82-88.e1.	2.4	7
97	Gender and Nationality Trends in Manuscripts Published in Prominent Gastroenterology Journals Between 1997 and 2017. <i>Digestive Diseases and Sciences</i> , 2022, 67, 367-376.	1.1	7
98	Predicting Effective Truvada PrEP Dosing Strategies With a Novel PK-PD Model Incorporating Tissue Active Metabolites and Endogenous Nucleotides (EN). <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A60-A60.	0.5	6
99	WATS for Barrett's surveillance. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 201-202.	0.5	6
100	Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	6
101	Palliative endoscopic spray cryotherapy to prevent worsening of dysphagia and improve quality of life in esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 219-219.	0.8	6
102	Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research. <i>Gastroenterology</i> , 2014, 146, 1586-1590.	0.6	5
103	Generic Measures of Quality of Life Are Not Correlated with Disease Activity in Eosinophilic Esophagitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3312-3321.	1.1	5
104	Stratifying Risk in Barrett's Esophagus With Low-grade Dysplasia: Making the Best of a (Not So) Bad Situation. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 963-965.	2.4	4
105	Natural History of the Post-ablation Esophagus. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2136-2145.	1.1	4
106	Durability of Endoscopic Treatment for Dysplastic Barrett's Esophagus. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 171-186.	0.3	4
107	How I Approach It: Care of the Post-Ablation Barrett's Esophagus Patient. <i>American Journal of Gastroenterology</i> , 2017, 112, 1487-1490.	0.2	3
108	Measuring Quality in Barrett's Endoscopy. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 889-891.	2.4	3

#	ARTICLE	IF	CITATIONS
109	Acceptability and Adequacy of a Non-endoscopic Cell Collection Device for Diagnosis of Barrett's Esophagus: Lessons Learned. <i>Digestive Diseases and Sciences</i> , 2022, 67, 177-186.	1.1	3
110	Screening strategies in gastroesophageal reflux disease: early identification of esophageal carcinoma. <i>Advances in Internal Medicine</i> , 2001, 47, 137-57.	0.9	3
111	New data on an old weapon: is argon plasma coagulation adequate treatment for dysplastic Barrett's esophagus?. <i>Endoscopy</i> , 2021, 53, 133-135.	1.0	2
112	Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e51-e63.	2.4	2
113	Reduced Esophageal Contractility Is Associated with Dysplasia Progression in Barrett's Esophagus: A Multicenter Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3631-3638.	1.1	2
114	Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia. <i>Clinical Cancer Research</i> , 2022, 28, 3761-3769.	3.2	2
115	Is intestinal metaplasia at the gastroesophageal junction really Barrett's esophagus?. <i>Current GERD Reports</i> , 2007, 1, 137-143.	0.1	1
116	Miscellaneous Diseases of the Esophagus: Foreign Bodies, Physical Injury, and Systemic and Dermatological Diseases. , 0, , 871-888.		1
117	Response to Braillon et al.. <i>American Journal of Gastroenterology</i> , 2016, 111, 900.	0.2	1
118	How to Promote the Academic Success of Junior Faculty Physicians in Gastroenterology. <i>Gastroenterology</i> , 2018, 155, 1293-1297.	0.6	1
119	Where is the finish line for endoscopic eradication therapy in Barrett's esophagus?. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 926-928.	0.5	1
120	Radiofrequency Ablation of Barrett's Esophagus: Have We Gone Too Far, or Not Far Enough?. <i>Current Gastroenterology Reports</i> , 2020, 22, 29.	1.1	1
121	Miscellaneous Diseases of the Esophagus: Foreign Bodies, Physical Injury, Systemic and Dermatological Diseases. , 0, , 205-219.		1
122	Surveillance after Treatment of Barrett's Esophagus Benefits Those with High-Grade Dysplasia or Intramucosal Cancer Most. <i>American Journal of Gastroenterology</i> , 2022, Publish Ahead of Print, .	0.2	1
123	eQTL set-based association analysis identifies novel susceptibility loci for Barrett's esophagus and esophageal adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	1.1	1
124	Endoscopic therapy for Barrett's esophagus. <i>Journal of Digestive Endoscopy</i> , 2012, 03, 017-022.	0.1	0
125	Presentation of the Julius M. Friedenwald Medal to Robert S. Sandler, MD, MPH. <i>Gastroenterology</i> , 2015, 148, 1466-1469.	0.6	0
126	Safety and efficacy of endoscopic spray cryotherapy for esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 83-83.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Efficacy of palliative liquid nitrogen spray cryotherapy in curbing progression of dysphagia in esophageal cancer.. Journal of Clinical Oncology, 2020, 38, 400-400.	0.8	0
128	Comparative effectiveness of trimodal therapy versus definitive chemoradiation in older adults with locally advanced esophageal cancer.. Journal of Clinical Oncology, 2022, 40, e16093-e16093.	0.8	0